|Active treatment for solid tumor and hematologic malignancies|
|Receipt of solid-organ transplant and taking immunosuppressive therapy|
|Receipt of CAR-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy)*|
|Moderate or severe primary immunodeficiency (eg, DiGeorge, Wiskott-Aldrich syndromes)|
|Advanced or untreated HIV infection (CD4 cell count <200 cells/microL, history of AIDS-defining illness without immune reconstitution, clinical manifestations of symptomatic HIV)|
|Active treatment with: |
In the United States, the Centers for Disease Control and Prevention lists the above conditions as examples of immunocompromising conditions that warrant additional primary COVID-19 vaccine series doses (eg, a three-dose primary mRNA vaccine series rather than a two-dose primary mRNA vaccine series) and an accelerated booster dose interval. This list is not exhaustive; other immunocompromising conditions, such as impaired splenic function, may also warrant the same vaccine adjustments. Refer to other UpToDate content for specifics of vaccine doses and intervals.People with the above conditions may also meet criteria for pre-exposure prophylaxis with specific monoclonal antibody regimens in the United States. Refer to UpToDate content on pre-exposure prophylaxis for more details.